Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Postoperative Thoracic Epidural Analgesia Versus Intravenous Patient-Controlled Analgesia For Liver and/or Pancreas

Phase 3

Completed

Conditions: Liver Cancer
Pancreatic Cancer

Interventions: Procedure: Thoracic Epidural Analgesia (TEA)
Procedure: Intravenous Patient-Controlled Analgesia (IVPCA)
Behavioral: Questionnaires
Behavioral: Pain Assessment

First Posted Date: 2011-09-22

Last Posted Date: 2020-02-12

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 178

Registration Number: NCT01438476

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

SB1518 for Patients With Myelodysplastic Syndrome (MDS)

Phase 2

Terminated

Conditions: Leukemia

Interventions: Drug: SB1518

First Posted Date: 2011-09-19

Last Posted Date: 2016-07-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 8

Registration Number: NCT01436084

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Pazopanib Hydrochloride in Treating Patients With Von Hippel-Lindau Syndrome

Phase 2

Completed

Conditions: Von Hippel-Lindau Syndrome

Interventions: Other: Laboratory Biomarker Analysis
Drug: Pazopanib Hydrochloride

First Posted Date: 2011-09-19

Last Posted Date: 2025-05-02

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 32

Registration Number: NCT01436227

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Inflammatory Response and Tissue Fibrosis/ Lymphatico-venous Bypass

Completed

Conditions: Breast Cancer
Genitourinary Cancer
Malignant Female Reproductive System Neoplasm
Melanoma
Sarcoma

Interventions: Procedure: Punch Biopsy

First Posted Date: 2011-09-13

Last Posted Date: 2015-05-06

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 21

Registration Number: NCT01433302

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Objective Assessment of Technical Skills in Cardiothoracic Surgery

Completed

Conditions: Other Surgical Procedures

Interventions: Other: Video Recording of CAB
Other: Surgical Video Assessments

First Posted Date: 2011-09-13

Last Posted Date: 2017-01-30

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 8

Registration Number: NCT01433029

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
The University of Texas Southwestern Medical Center in Dallas, Dallas, Texas, United States
🇺🇸
Texas Heart Institute at St. Luke's Episcopal Hospital, Houston, Texas, United States

and more 3 locations

Lacosamide in Preventing Seizures in Participants With Malignant Glioma

Not Applicable

Terminated

Conditions: Malignant Glioma

Interventions: Drug: Lacosamide
Other: Placebo

First Posted Date: 2011-09-12

Last Posted Date: 2018-12-19

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 37

Registration Number: NCT01432171

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Phase 1 Trial With SIR-Spheres and Cetuximab +/- Erlotinib

Phase 1

Withdrawn

Conditions: Advanced Cancers

Interventions: Device: SIR-Spheres
Drug: Cetuximab
Drug: Erlotinib
Procedure: Break-Through Scan

First Posted Date: 2011-09-12

Last Posted Date: 2013-04-09

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT01432119

Mirror Grant - Toward an Understanding of Body Image Adaptation Following Surgical Treatment for Head and Neck Cancer

Completed

Conditions: Head and Neck Cancer

Interventions: Behavioral: Interview
Behavioral: Questionnaire

First Posted Date: 2011-09-12

Last Posted Date: 2017-08-04

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 25

Registration Number: NCT01432132

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Temozolomide, Memantine Hydrochloride, Mefloquine, and Metformin Hydrochloride in Treating Patients With Glioblastoma Multiforme After Radiation Therapy

Phase 1

Terminated

Conditions: Glioblastoma
Gliosarcoma
Supratentorial Glioblastoma

Interventions: Drug: Memantine Hydrochloride
Drug: Mefloquine
Drug: Metformin Hydrochloride
Drug: Temozolomide

First Posted Date: 2011-09-08

Last Posted Date: 2025-05-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 144

Registration Number: NCT01430351

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients

Phase 1

Completed

Conditions: Solid Tumors
Advanced Cancers

Interventions: Drug: Pazopanib
Drug: Everolimus

First Posted Date: 2011-09-08

Last Posted Date: 2023-06-06

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 62

Registration Number: NCT01430572

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy